Venture Map · Round
Highlight Therapeutics — Other · €22.6M
Announced 2021-02-03 · Valencia · Biotech / Immuno-oncology
Highlight Therapeutics, formerly Bioncotech, is a clinical-stage biotech. It closed €22.6M co-led by Columbus Venture Partners' Life Science Fund II and Advent Life Sciences, with CDTI (via Innvierte, €3.6M) and existing shareholders also investing. The money funds Phase 2 combination trials of its RNA-based drug BO-112. No series name was given.
RoundOther
Amount€22.6M
LeadNot disclosed
Date2021-02-03
CityValencia
SectorBiotech / Immuno-oncology
The company
Investors 3
AAdvent Life Sciences
CCDTI (Innvierte)
www.cdti.es
CColumbus Venture Partners
www.columbusvp.com